BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 24412773)

  • 21. N-terminal pro-B-type natriuretic peptide as a predictor of repeat coronary revascularization.
    Sir JJ; Chung WY; Hwang SJ; Kang HJ; Cho YS; Koo BK; Chae IH; Choi DJ; Kim HS; Sohn DW; Kim CH; Oh BH; Park YB; Choi YS
    Int J Cardiol; 2008 Jun; 126(3):322-32. PubMed ID: 17544525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of N-terminal probrain natriuretic peptide to predict mortality or detect acute ischemia in patients with coronary artery disease.
    Ndrepepa G; Braun S; Mehilli J; Schömig A; Kastrati A
    Cardiology; 2008; 109(4):249-57. PubMed ID: 17873489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate.
    Reinhard H; Hansen PR; Persson F; Tarnow L; Wiinberg N; Kjær A; Petersen CL; Winther K; Parving HH; Rossing P; Jacobsen PK
    Nephrol Dial Transplant; 2011 Oct; 26(10):3242-9. PubMed ID: 21372253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients.
    Cosson E; Nguyen MT; Pham I; Pontet M; Nitenberg A; Valensi P
    Diabet Med; 2009 Sep; 26(9):872-9. PubMed ID: 19719707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of serum N-terminal pro-brain natriuretic peptide to predict in-stent restenosis in patients with preserved left ventricular function and normal troponin I levels.
    Hong SN; Ahn Y; Yoon NS; Lee KH; Kim YS; Hwang SH; Lee SR; Kim KH; Park HW; Hong YJ; Kim JH; Jeong MH; Cho JG; Park JC; Kang JC
    Am J Cardiol; 2007 Apr; 99(8):1051-4. PubMed ID: 17437726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.
    Harutyunyan MJ; Mathiasen AB; Winkel P; Gøtze JP; Hansen JF; Hildebrandt P; Jensen GB; Hilden J; Jespersen CM; Kjøller E; Kolmos HJ; Gluud C; Kastrup J;
    Scand J Clin Lab Invest; 2011 Feb; 71(1):52-62. PubMed ID: 21108561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Joint effects of N-terminal pro-B-type-natriuretic peptide and C-reactive protein vs angiographic severity in predicting major adverse cardiovascular events and clinical restenosis after coronary angioplasty in patients with stable coronary artery disease.
    Dai DF; Hwang JJ; Lin JL; Lin JW; Hsu CN; Lin CM; Chiang FT; Lai LP; Hsu KL; Tseng CD; Tseng YZ
    Circ J; 2008 Aug; 72(8):1316-23. PubMed ID: 18654020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-terminal pro-B-type natriuretic peptide level is depressed in patients with significant coronary artery disease who have high body mass index.
    Hong SN; Ahn Y; Yoon NS; Moon JY; Kim KH; Hong YJ; Park HW; Kim JH; Jeong MH; Cho JG; Park JC; Kang JC
    Int Heart J; 2008 Jul; 49(4):403-12. PubMed ID: 18753724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.
    Buchner S; Debl K; Barlage S; Griese D; Fredersdorf S; Jeron A; Lubnow M; Müller T; Muders F; Holmer S; Riegger GA; Luchner A
    Clin Chem Lab Med; 2010 Jun; 48(6):875-81. PubMed ID: 20441480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human coronary atherosclerosis modulates cardiac natriuretic peptide release.
    Barbato E; Rubattu S; Bartunek J; Berni A; Sarno G; Vanderheyden M; Delrue L; Zardi D; Pace B; De Bruyne B; Wijns W; Volpe M
    Atherosclerosis; 2009 Sep; 206(1):258-64. PubMed ID: 19237156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitive cardiac troponins and N-terminal pro-B-type natriuretic peptide in stable coronary artery disease: correlation with left ventricular function as assessed by myocardial strain.
    Smedsrud MK; Gravning J; Omland T; Eek C; Mørkrid L; Skulstad H; Aaberge L; Bendz B; Kjekshus J; Edvardsen T
    Int J Cardiovasc Imaging; 2015 Jun; 31(5):967-73. PubMed ID: 25788439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Asymptomatic ischemic heart dysfunction, echocardiographic changes and NT-proBNP during 2-years observation].
    Skrzypek A; Nessler J
    Przegl Lek; 2014; 71(7):378-83. PubMed ID: 25338333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy.
    Lindahl B; Lindbäck J; Jernberg T; Johnston N; Stridsberg M; Venge P; Wallentin L
    J Am Coll Cardiol; 2005 Feb; 45(4):533-41. PubMed ID: 15708700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-Terminal pro-B-type natriuretic peptide and coronary microvascular dysfunction in women with preserved ejection fraction: A report from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) study.
    Jones E; Wei J; Nelson MD; Bakir M; Mehta PK; Shufelt C; Minissian M; Sharif B; Pepine CJ; Handberg E; Cook-Wiens G; Sopko G; Bairey Merz CN
    PLoS One; 2020; 15(12):e0243213. PubMed ID: 33270715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aminoterminal B-type pro-natriuretic peptide as a marker of recovery after high-risk coronary artery bypass grafting in patients with ischemic heart disease and severe impaired left ventricular function.
    Rothenburger M; Stypmann J; Bruch C; Wichter T; Hoppe M; Drees G; Berendes E; Huelsken G; Loeher A; Welp H; Röttger C; Schmid C; Scheld HH; Tjan TD
    J Heart Lung Transplant; 2006 May; 25(5):596-602. PubMed ID: 16678040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
    Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
    Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk stratification in stable coronary artery disease: superiority of N-terminal pro B-type natriuretic peptide over high-sensitivity C-reactive protein, gamma-glutamyl transferase, and traditional risk factors.
    Bode E; Wuppinger T; Bode T; Alber H; Ulmer H; Pachinger O; Mair J
    Coron Artery Dis; 2012 Mar; 23(2):91-7. PubMed ID: 22157356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide.
    Jarai R; Iordanova N; Jarai R; Raffetseder A; Woloszczuk W; Gyöngyösi M; Geyer G; Wojta J; Huber K
    Eur Heart J; 2005 Feb; 26(3):250-6. PubMed ID: 15618049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NT-proBNP levels in the evaluation of right ventricular dysfunction in patients with coronary artery disease and abnormal left ventricular wall motion: a magnetic resonance imaging study.
    Krittayaphong R; Boonyasirinant T; Saiviroonporn P; Udompunturak S
    Coron Artery Dis; 2008 Nov; 19(7):481-7. PubMed ID: 18923244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NT-ProBNP serum levels reflect severity and extent of ischemia in patients admitted with non-ST-elevation acute coronary syndrome.
    Riezebos RK; Ronner E; Tijssen JG; Laarman GJ
    Acute Card Care; 2006; 8(1):51-7. PubMed ID: 16720429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.